Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma

Hepatology Research

Volumn 24, Issue 4, 2002, Pages 404-412

  Uenishi, Takahiro ^a   Kubo, Shoji ^a   Hirohashi, Kazuhiro ^a   Tanaka, Hiromu ^a   Shuto, Taichi ^a   Yamamoto, Takatsugu ^a   Tamori, Akihiro ^a   Hai, Seikan ^a   Kinoshita, Hiroaki ^a   Nishiguchi, Shuhei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aminotransferase activity; Hepatic resection; Postoperative outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0036903732     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00147-X     Document Type: Article

References (35)

1. Takenaka K, Yamamoto K, Taketomi A, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995;22:20-4.
2. Chen M, Jeng L, Lee W, et al. Surgical results in patients with dual hepatitis B- or C-related hepatocellular carcinoma compared with B- or C-related hepatocellular carcinoma. Surgery 1998;123:554-9.
3. Kubo, S, Nishiguchi S, Shuto T, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 1999;90:162-70.
4. Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000;135:1456-9.
5. Kubo S, Hirohashi K, Tanaka H, et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000;24:1559-65.
6. Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-94.
7. Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996;77:1050-5.
8. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963-7.
9. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
10. Osaka hepatocellular Carcinoma Prevention Study Group, Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9.
11. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653-9.
12. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943-50.
13. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
14. IHIT Study Group, Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of chronic and nonchronic patients with chronic hepatitis C in Japan. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-81.
15. International Interferon-Alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-9.
16. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
17. Nishiguchi S, Siomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
18. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
19. Kubo S, Nishiguchi S, Tamori A, et al. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology 2000;47:1100-2.
20. Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 2001;92:59-66.
21. Couinaud C. Lobes et segments hepatiques. Notes sur larchitecture anatomique et chirrgicale du foie. Presse Med 1954;62:709-11.
22. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
23. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, 1st ed.. Tokyo, Japan: Kanahara, 1997.
24. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
25. Knodell RG, Ishak KG, Black WC, et al. Formation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
26. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classisfication of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
27. Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathological features and results of surgical treatment. Ann Surg 1990;211:277-87.
28. Jwo SC, Chiu JH, Chan GY, et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Ann Surg 1991;214:114-7.
29. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488-98.
30. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-24.
31. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994;106:720-7.
32. Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy: result of multivariate analysis. Ann Surg 1996;224:591-5.
33. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
34. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
35. Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;49:113-5.